1. CLINICAL DILEMMAS IN HEART FAILURE:

3. ESC HF Guidelines: Changes From 2012 for Chronic HF Management

4. Evolution of Neurohormonal Blockers

5. Neurohormonal Blockade in HF

6. Impact of Beta-Blockade, ACEi, and ARB Therapy in Chronic HF

7. MRAs: Mechanism of Action

8. RALES: Mortality Reduction With Spironolactone

9. MRAs in Heart Failure

10. Neurohormonal Activation: Good and Bad

11. PARADIGM-HF Primary Results: Significant Reduction in Primary Endpoints, CV Death, and All-Cause Mortality

12. SOLVD: Enalapril vs Placebo in HFrEF

13. PARADIGM-HF: Robustness of the Results

14. ACEi - ARNi in Chronic HF: A 25+ Year Story

15. Terminology Within Heart Failure

16. PARADIGM-HF: Secondary Outcomes and Patient-Reported Outcomes

17. PARADIGM-HF: NYHA Functional Class at Baseline

18. ESC Guidelines for HF: Pharmacological Treatments in Symptomatic (NYHA Class II-IV) HFrEF - Target Dosing

19. Natriuretic Peptides in HF

20. Sacubitril/Valsartan in HFrEF: Starting Dose and Dose Titration

21. PARADIGM-HF: Adverse Events

22. Abbreviations

23. Abbreviations (cont)